

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

COMMONWEALTH OF PENNSYLVANIA
DEPARTMENT OF STATE
BUREAU OF PROFESSIONAL AND OCCUPATIONAL AFFAIRS

F I N A L M I N U T E S

MEETING OF:

**STATE BOARD OF PHARMACY
VIA TELECONFERENCE**

TIME: 10:33 A.M.

PENNSYLVANIA DEPARTMENT OF STATE

December 1, 2020

1 State Board of Pharmacy
2 December 1, 2020

3
4
5 BOARD MEMBERS:

6
7 Terry M. Talbott, R.Ph., Chairperson
8 K. Kalonji Johnson, Commissioner, Bureau of
9 Professional and Occupational Affairs
10 Robert B. Frankil, R.Ph., Vice Chairman
11 Janet Getzey Hart, R.Ph., Secretary
12 Patrick M. Greene, Esquire, Office of Attorney
13 General
14 John R. Slagle, R.Ph. - Absent
15 Christine Roussel, Pharm.D., BCOP, BCSCP
16
17

18 BUREAU PERSONNEL:

19
20 Juan A. Ruiz, Esquire, Board Counsel
21 Ray Michalowski, Esquire, Senior Board Prosecution
22 Liaison
23 Glenn P. Masser, Esquire, Board Prosecutor
24 Angela B. Lucci, Esquire, Board Prosecutor
25 Alice Glasser, Esquire, Board Prosecutor
26 Melanie Zimmerman, R.Ph., Executive Secretary
27 Theodore Stauffer, Executive Secretary, Bureau of
28 Professional and Occupational Affairs
29 Andrew LaFratte, MPA, Policy Fellow, Department of
30 State
31 Carolyn DeLaurentis, Deputy Chief Counsel, Prosecution
32 Division
33
34

35 ALSO PRESENT:

36
37 Alicia Palombo, Pharm.D., Pharmacy Regulatory Affairs
38 Advisor at CVS Health
39 Andrew Felter, Manager of Pharmacy Compliance and
40 Regulatory Relations, Wegmans Food Markets
41 Barbara Knightly, Executive Vice President of
42 Regulatory Affairs and Quality Operations, Pentec
43 Health & International Academy of Compounding
44 Pharmacists
45 Carl Harting, CVS Health
46 Christopher Miller, Pharm.D., Giant Eagle
47 David Klinger, System Director, Operations
48 & Compliance, Geisinger Health System
49 James Reed, Area Healthcare Supervisor, Walgreens
50 Christopher Dang

State Board of Pharmacy
December 1, 2020

ALSO PRESENT: (Continued)

1
2
3
4
5
6
7 Christine Renfer, CVS Health
8 Gayle Scott
9 Frank Trollo, Central Admixture Pharmacy Services
10 Grace Fisher, Giant Food Stores
11 Gregory Smith, Director of Pharmacy, Central Admixture
12 Pharmacy Services
13 Heather Coy, AllianceRx Walgreens Prime
14 Jen Smeltz, Executive Director, Consumer Protection
15 and Professional Licensure Committee
16 Jennifer Welch, ACME/Sav-on Pharmacy
17 Jessica Adams, Pharm.D., BCPS, AIHIVP
18 Jerry J. Livingston, Executive Director, Senate
19 Consumer Protection & Professional Licensure
20 Committee
21 Judy Kutchman, AllianceRx Walgreens Prime
22 Leigh Shirley, Giant Food Stores
23 Lisa Scannapieco, Director of Pharmacy Education and
24 Clinical Integration, Pentec Health
25 Nicole Sidle, Majority Committee Executive Director,
26 House Professional Licensure Committee
27 Patricia A. Epple, CEO, Pennsylvania Pharmacists
28 Association
29 Victoria Elliott, RPh, MBA, CAE, CEO, Pennsylvania
30 Pharmacists Association
31 Patrick Holtz
32 Steve Sheaffer, Pennsylvania Society of Health-System
33 Pharmacists
34 Margaret Durkin, Bravo Group
35 Steven Zahn, Pharmacy Inspector, Bureau of Enforcement
36 and Investigation, Department of State
37 Catherine Lutz, Pharmacy Inspector, Bureau of
38 Enforcement and Investigation, Department of State
39 Kimberly Adams, Chief of Fiscal Management, Bureau of
40 Finance and Operations
41 Amanda Richards, Fiscal Management Specialist 2,
42 Bureau of Finance and Operations
43 Shannon Boop, Fiscal Management Specialist 1, Bureau
44 of Finance and Operations
45 Michelle Witmer, Fiscal Management Specialist 1,
46 Bureau of Finance and Operations
47 Jill McCormack
48 Kristen Motley
49 Kimberly Mehta
50

1 ***

2 State Board of Pharmacy

3 December 1, 2020

4 ***

5 [Pursuant to Section 708(a)(5) of the Sunshine Act, at
6 9:00 a.m., the Board entered into Executive Session
7 with Juan A. Ruiz, Esquire, Board Counsel, to receive
8 legal advice and engage in quasi-judicial
9 deliberations. The Board returned to open session at
10 10:30 a.m.]

11 ***

12 The regularly scheduled meeting of the State
13 Board of Pharmacy was held on Tuesday, December 1,
14 2020. Terry M. Talbott, R.Ph., Chairperson, called
15 the meeting to order at 10:33 a.m.

16 K. Kalonji Johnson, Commissioner, Bureau of
17 Professional and Occupational Affairs, was not present
18 during commencement of the meeting.

19 ***

20 Introduction of the Board Members/Audience
21 [Chairperson Talbott read the attendee list and
22 requested Board members introduce themselves.

23 Chairperson Talbott also noted the meeting was
24 being recorded, and those who remained on the line
25 were giving their consent to being recorded.]

1 ***

2 Report of Prosecutorial Division

3 [Angela B. Lucci, Esquire, Board Prosecutor, presented
4 the Consent Agreement for Case No. 19-54-015920 & 20-
5 54-007648.

6 Chairperson Talbott recused herself from
7 deliberations.]

8 ***

9 [K. Kalonji Johnson, Commissioner, Bureau of
10 Professional and Occupational Affairs, entered the
11 meeting at 10:45 a.m.]

12 ***

13 [Glenn P. Masser, Esquire, Board Prosecutor, presented
14 the Consent Agreement for Case No. 20-54-000145 and
15 Case No. 20-54-002319.

16 Mr. Greene recused himself from deliberations
17 regarding Case No. 20-54-002319.]

18 ***

19 [Alice Glasser, Esquire, Board Prosecutor, presented
20 the Consent Agreement for Case No. 20-54-010276.

21 Mr. Greene recused himself from deliberations.]

22 ***

23 MR. GREENE:

24 I would like to make a motion that we
25 approve the Consent Agreement at Case No.

1 19-54-015920 & 20-54-007648.]

2 CHAIRPERSON TALBOTT:

3 We have a motion. Do we have a second?

4 MR. FRANKIL:

5 Second.

6 CHAIRPERSON TALBOTT:

7 Any discussion? Call the vote.

8

9 Roussel, aye; Hart, aye; Greene, aye;

10 Frankil, aye; Johnson, aye; Talbott,

11 recuse.

12 [The motion carried. Chairperson Talbott recused
13 herself from deliberations and voting on the motion.
14 The respondent's name is CVS Pharmacy 4077 and Sherese
15 A. Pearl.]

16

17 MR. GREENE:

18 I would like to make a motion that we
19 approve the Consent Agreement at Case No.
20 20-54-000145.]

21 CHAIRPERSON TALBOTT:

22 We have a motion. Do we have a second?

23 MR. FRANKIL:

24 Second.

25 CHAIRPERSON TALBOTT:

1 Any discussion? Call the vote.

2

3 Roussel, aye; Hart, aye; Greene, aye;

4 Frankil, aye; Johnson, aye; Talbott, aye.

5 [The motion carried unanimously. The Respondent's
6 name is Meds for Vets.]

7

8 MR. FRANKIL:

9 I make a motion we approve the Consent
10 Agreement at Case No. 20-54-002319.]

11 CHAIRPERSON TALBOTT:

12 Do we have a second?

13 DR. ROUSSEL:

14 Second.

15 CHAIRPERSON TALBOTT:

16 Any further discussion? Call the vote.

17

18 Roussel, aye; Hart, aye; Greene, recuse;

19 Frankil, aye; Johnson, aye; Talbott, aye.

20 [The motion carried. Mr. Greene recused himself from
21 deliberations and voting on the motion. The

22 Respondent's name is Joel Anthony Gonzalo, R.Ph.]

23

24 MR. FRANKIL:

25 I make a motion that we approve the

1 Consent Agreement at Case No. 20-54-
2 010276.]

3 CHAIRPERSON TALBOTT:

4 Do we have a second?

5 DR. ROUSSEL:

6 Second.

7 CHAIRPERSON TALBOTT:

8 Any further discussion? Call the vote.

9

10 Roussel, aye; Hart, aye; Greene, recuse;
11 Frankil, aye; Johnson, aye; Talbott, aye.

12 [The motion carried. Mr. Greene recused himself from
13 deliberations and voting on the motion. The
14 Respondent's name is Nicholas K. Loukas, R.Ph.]

15

16 Appointment - Bureau of Finance and Operations Annual
17 Budget Presentation

18 [Kimberly Adams, Chief of Fiscal Management, Bureau of
19 Finance and Operations, Department of State, addressed
20 licensee population from a revenue standpoint. She
21 noted an increase in FY 2016-2018 of 1,702 licensees
22 and an increase in FY 2018-2020 of 3,431 with an
23 additional 108 licensees as of this morning for a
24 current renewable licensee count of 41,543. She also
25 provided a breakdown of licensees by class.

1 Ms. Adams reviewed revenue by source, noting 97.3%
2 of revenue is from biennial renewals. She reviewed
3 categories and actual revenue for FY 2018-2019 and FY
4 2019-2020, noting the biennial total. She mentioned
5 the last renewal fee increase was in 2005. She noted
6 all biennial renewal fees for different licensee
7 classes.

8 Ms. Adams provided a categorical breakdown of
9 expenses for FY 2018-2019 and FY 2019-2020 with a
10 current budget for FY 2020-2021 and expenses as of
11 November 10, 2020. She noted a recent increase in
12 expenses and the total recent expenditures.

13 Ms. Adams reviewed revenues and expenses for FY
14 2021-2022, reflecting the current budget. She stated
15 revenues continue to exceed expenses.

16 Ms. Adams reviewed Board member expenses, noting
17 current expenses figure with \$25,000 budgeted for FY
18 2020-2021, which appeared sufficient and would carry
19 into FY 2021-2022. She stated any excess money
20 budgeted would remain in the restricted account for
21 the Board's use.]

22

23 Approval of minutes of the October 15, 2020 meeting
24 CHAIRPERSON TALBOTT:

25 We do have the approval of the meeting

1 minutes from October 15.

2 Did anyone see any corrections to
3 those minutes? If not, I would entertain
4 a motion to accept those as final.

5 MR. FRANKIL:

6 So moved.

7 CHAIRPERSON TALBOTT:

8 Frankil moved. Do I have a second?

9 COMMISSIONER JOHNSON:

10 Second.

11 CHAIRPERSON TALBOTT:

12 Any discussion? All in favor of
13 approving the minutes as final, say aye,
14 please?

15 [The motion carried unanimously.]

16 ***

17 Report of Board Counsel

18 [Juan A. Ruiz, Esquire, Board Counsel, updated the
19 Board on the status of the injectable regulation. He
20 mentioned receiving four formal comments that would be
21 on the next meeting's agenda for discussion and to
22 start the process of promulgating the final
23 regulation.

24 Mr. Ruiz announced Act 116 of 2020 regarding the
25 Bureau of Professional and Occupational Affairs (BPOA)

1 continuing education carryover passed, which allows
2 individuals with excess continuing education credits
3 to carry those over into the next biennial reporting
4 period. He stated the Board would need to decide how
5 much could be carried over. He noted the Act was not
6 mandatory.

7 Chairperson Talbott requested an update from
8 Commissioner Johnson as to when the Pennsylvania
9 Licensing System (PALS) authorization to administer
10 injectables for pharmacy intern's application would be
11 operational, so interns may assist with the flu and
12 COVID vaccines.

13 Commissioner Johnson noted striving for January
14 2021. He mentioned discussions with legal and policy
15 to find ways to accommodate interns if PALS
16 development was delayed from January to sometime later
17 in the first quarter.

18 Chairperson Talbott emphasized the importance of
19 citizens being able to receive immunizations and
20 strongly implored Commissioner Johnson to find a way
21 to work around PALS to be able to have as many people
22 as possible provide immunizations. She offered
23 Commissioner Johnson assistance from the Board on
24 subject matter and information.

25 Mr. Ruiz informed the Board of Governor Wolf's

1 approval of House Bill 770, which is now Act 140 of
2 2020, allowing the ability to register pharmacy
3 technicians.

4 Mr. Michalowski noted the bill to be very
5 regulation-dependent and the Board and Board Counsel
6 would have the assistance of Ms. Lucci regarding the
7 analysis and creating guidelines.]

8

9 Report of Probable Cause Screening Committee
10 [Patrick M. Greene, Esquire, Office of Attorney
11 General, noted signing off on one Petition for
12 Appropriate Relief.]

13

14 Report of Board Chairperson
15 [Terry M. Talbott, R.Ph., Chairperson, requested Dr.
16 Roussel provide a summary of the Food and Drug
17 Administration (FDA) Meeting that was held in October.

18 Dr. Roussel addressed the Intergovernmental
19 Meeting on Drug Compounding, noting presentations from
20 the FDA and representatives from the National
21 Association of Boards of Pharmacy and individual state
22 board of pharmacies. She mentioned discussions on
23 animal compounding, FDA waivers, and detailed
24 information about contamination of hand sanitizers
25 with methanol. She noted the MOU as the main topic

1 and discussions regarding state implementation and
2 involvement from the National Association of Boards of
3 Pharmacy (NABP).

4 Ms. Hart addressed her attendance at the
5 Accreditation Council for Pharmacy Education (ACPE)
6 virtual evaluation of Wilkes University Nesbitt School
7 of Pharmacy accreditation renewal. She did not
8 believe the final accreditation report would show any
9 deep findings.

10 Chairperson Talbott encouraged those who want to
11 participate in the upcoming Duquesne evaluation and
12 others to decide by January.]

13 ***

14 Report of Board Chairperson - Election of Officers

15 CHAIRPERSON TALBOTT:

16 Do I have any nominations for the role of
17 chairman?

18 MR. GREENE:

19 I nominate Janet Hart for the position of
20 Board chairperson.

21 CHAIRPERSON TALBOTT:

22 Do I have a second for Janet?

23 MR. FRANKIL:

24 Yes. I will second that.

25 CHAIRPERSON TALBOTT:

1 All right. Do we have any other
2 nominations?

3 Move the nominations be closed,
4 please. Pat, do you move that?

5 MR. GREENE:

6 Yes. I'll make that motion.

7 CHAIRPERSON TALBOTT:

8 Okay. Second?

9 MR. FRANKIL:

10 Motion seconded.

11 CHAIRPERSON TALBOTT:

12 All those in favor of Janet being
13 chairperson of the Board, please say aye.
14 Any opposed?

15 [The motion carried unanimously.]

16 ***

17 CHAIRPERSON TALBOTT:

18 Do we have a nomination for vice chair?

19 MR. GREENE:

20 Yes. I nominate Robert Frankil for the
21 position of vice chair.

22 CHAIRPERSON TALBOTT:

23 Okay. Do we have a second?

24 MS. HART:

25 I'll second.

1 CHAIRPERSON TALBOTT:

2 Moved and seconded. Are there any other
3 nominations for vice chair? Hearing
4 none.

5 Can we close the nominations, Pat?
6 Do you move to close the nominations?

7 MR. GREENE:

8 Yes.

9 CHAIRPERSON TALBOTT:

10 Okay. Janet, second?

11 MS. HART:

12 Second.

13 CHAIRPERSON TALBOTT:

14 All those in favor of Rob Frankil being
15 vice chair, please signify by saying aye.
16 Any opposed?

17 [The motion carried unanimously.]

18 ***

19 CHAIRPERSON TALBOTT:

20 Do we have a nomination for secretary?

21 MR. FRANKIL:

22 I nominate Christine Roussel for
23 secretary.

24 CHAIRPERSON TALBOTT:

25 Okay. Pat, would you like to second?

1 MR. GREENE:

2 Second.

3 CHAIRPERSON TALBOTT:

4 Are there any other nominations? Can we
5 have a motion to close the nominations?
6 Rob?

7 MR. FRANKIL:

8 Closed.

9 CHAIRPERSON TALBOTT:

10 Pat, would you second?

11 MR. GREENE:

12 Second.

13 CHAIRPERSON TALBOTT:

14 All those in favor of Christine Roussel
15 being our secretary, please signify by
16 saying aye. Any opposed?

17 [The motion carried unanimously.]

18 ***

19 Report of Board Chairperson - Committee Assignments
20 [Melanie Zimmerman, R.Ph., Executive Secretary,
21 addressed committee assignments. The Board decided
22 Ms. Hart will serve as the chairperson and Ms. Talbott
23 as the alternate on the ADA Committee. Mr. Greene
24 will serve as Chairman and Dr. Roussel as the
25 alternate on the Probable Cause Screening Committee.

1 Mr. Frankil will serve as Chairman, along with Dr.
2 Roussel and Mr. Slagle on the Pharmacy Application
3 Review Committee, with Ms. Talbott as the alternate.
4 The CPR/Injectables Training Program Approval
5 Committee will stay the same with Rob Frankil as the
6 Chairman and member Terry Talbott. The Act 41
7 Committee will stay the same - Janet Hart as the
8 Chairperson and members Terry Talbott and Rob Frankil.
9 The Medical Marijuana Advisory Board Committee will
10 continue to consist of Ms. Hart.

11 Chairperson Talbott suggested creating a
12 Regulatory Committee to start drafting and pulling
13 information together. Chairperson Talbott will serve
14 as chair, along with Ms. Hart and Dr. Roussel.]

15 ***

16 Report of Commissioner

17 [K. Kalonji Johnson, Commissioner, Bureau of
18 Professional and Occupational Affairs, gave a note of
19 gratitude to the Board, stakeholders, and members of
20 the audience who have all contributed in the past
21 several months. He commented that the Board had been
22 incredible in terms of showing a level of patience and
23 imagination in making sure the work gets done.

24 Commissioner Johnson noted it to be a privilege
25 and honor to work with Chairperson Talbott and looked

1 forward to working with the new chair as well.]

2 ***

3 Report of Executive Secretary

4 [Melanie Zimmerman, R.Ph., Executive Secretary,

5 questioned whether Mr. Michalowski received any

6 articles for the Board's newsletter from the

7 Department of Health concerning the Prescription Drug

8 Monitoring Program.

9 Mr. Michalowski noted not receiving anything but
10 will try to provide something by the end of the week.

11 Ms. Zimmerman reported pharmacist renewals are
12 running at about 76% and encouraged everyone to renew
13 before December 29 because there is no grace period.

14 Chairperson Talbott requested individuals on the
15 call tell stakeholder groups and asked Board members
16 to reach out to networks to remind everyone that there
17 is no grace period.]

18 ***

19 Applications

20 MR. GREENE:

21 I make a motion that we deny Bogomir
22 Kuhar's Application for Exemption from
23 the Child Abuse CE Program.

24 MR. FRANKIL:

25 Second.

1 CHAIRPERSON TALBOTT:

2 Any discussion? All in favor, say aye,
3 please? Any opposed?

4 [The motion carried unanimously.]

5 ***

6 MR. GREENE:

7 I make a motion we approve the
8 application of Saban Kar and reduce the
9 required intern hours by 500 hours
10 requiring the applicant to earn 1000
11 hours.

12 MR. FRANKIL:

13 Second.

14 CHAIRPERSON TALBOTT:

15 Any discussion on that motion? Hearing
16 none. All in favor, please say ay. Any
17 opposed?

18 [The motion carried unanimously.]

19 ***

20 New Business

21 [Melanie Zimmerman, R.Ph., Executive Secretary, noted
22 prior discussion during Executive Session that the
23 Board has no nominations for the National Association
24 of Boards of Pharmacy awards.

25 Ms. Zimmerman announced Chairperson Talbott

1 agreed to the request from the Pennsylvania
2 Pharmacists Association (PPA) for her to provide a
3 State Board of Pharmacy update presentation in
4 January.]

5 ***

6 MS. HART:

7 I make a motion we be allowed to have a
8 presentation for PPA on State Board of
9 Pharmacy updates for the upcoming (PPA)
10 meeting and additional (PPA) meetings in
11 the future.

12 CHAIRPERSON TALBOTT:

13 Do we have a second?

14 MR. FRANKIL:

15 Second.

16 CHAIRPERSON TALBOTT:

17 Any discussion? All in favor, please say
18 aye. Any opposed?

19 [The motion carried unanimously.]

20 ***

21 For the Board's Information

22 [Melanie Zimmerman, R.Ph., Executive Secretary, noted
23 NABP's position on new federal importation rules as
24 being concerned about the safety of the drug supply
25 and shortages in Canada and the United States.]

1
2 Report of Board Counsel (Continued)

3 [Juan A. Ruiz, Esquire, Board Counsel, informed the
4 Board that the FDA announced the memorandum of
5 understanding (MOU) to be signed by the states became
6 available on October 26, 2020, giving states a year to
7 sign the MOU. He explained MOU as reporting and
8 dealing with section 503A compounding pharmacies that
9 do mostly interstate compounding. He stated it
10 requires boards to report any complaints or issues
11 concerning that to the FDA.

12 Mr. Michalowski noted already being a signatory
13 under 20.88 and having the ability to share
14 information back and forth between with the FDA and
15 the Department of Health, which is a helpful in
16 evaluating the MOU.

17 Mr. Michalowski referred to MOU Section III
18 regarding substance of the agreement, where section
19 III.a details investigation complaints relating to
20 compounded human drug products distributed outside the
21 state. He noted investigating complaints and keeping
22 records but having very few cases. He also noted one
23 out-of-state case so far was not human and involved
24 vet products and no cases as of yet where MOU would
25 apply.

1 Mr. Michalowski addressed section III.a.5 that
2 requires reporting within 5 days of receiving a
3 complaint, noting concern because sometimes there is
4 clear evidence and other times something may not be
5 known at the time of the complaint.

6 Mr. Michalowski referred to section III.a.6,
7 where the State Board of Pharmacy would inform the FDA
8 when there are issues with non-pharmacy compounding.
9 He mentioned Pennsylvania has an umbrella organization
10 for licensing and would include medical and
11 osteopathic boards.

12 Mr. Michalowski stated the 5-day requirement is
13 difficult, but the actual reporting and recordkeeping
14 is fairly easy to do because of having already signed
15 the previous MOU that allows boards to share
16 information with them if the information sharing
17 network is functional.

18 Mr. Michalowski referred to section III.a.7.b
19 regarding the distribution of inordinate amounts of
20 compounded human drug products interstate, where it
21 anticipates the State Board of Pharmacy or some other
22 agency within the state would keep track and know the
23 total number of prescription orders for sterile
24 compounded human drug products distributed.

25 Mr. Michalowski was not sure how to comply with

1 section III.a.7.b when there was no way of monitoring
2 that, and most of it did not seem to be optional. He
3 noted Mr. McMurry could review the technical ways of
4 what we would share, and the 20.88 agreement that we
5 already signed would help with those matters. He
6 expressed a concern regarding monitoring the
7 inordinate amounts of compounded human drug products
8 being shipped interstate.

9 Dr. Roussel addressed discussions with the
10 National Association of Boards of Pharmacy, where
11 there was open forum to allow different states to
12 discuss barriers. She noted states that have separate
13 licensure felt there was no need for those barriers.
14 She commented that surveys sent in annually offered
15 that as one of the main suggestions.

16 Dr. Roussel announced NABP received a National
17 Institutes of Health (NIH) grant to be able to put
18 forth the system, which was up and running in June
19 2020 to allow reported data. She believed it to be
20 important for public safety and to ensure patients
21 have access to vital medication. She noted compounded
22 products are used in many different ways.

23 Mr. Michalowski believed a survey would be the
24 best route but mentioned a difficulty in Pennsylvania
25 with every pharmacy possibly being a compounding

1 pharmacy. It would have to be a requirement for every
2 pharmacy or some sort of threshold would be needed.
3 He noted being unsure whether to necessitate the
4 requirement by regulation or administratively but
5 would need some manner of that kind of reporting.

6 Mr. Michalowski also noted not being sure whether
7 the Department of Health would be involved because of
8 the strange setup in Pennsylvania, where the Board of
9 Pharmacy does not have control over nearly as much of
10 the inflow and outflow of pharmaceuticals because of
11 the way the drug act is set up, noting he would reach
12 out to them, along with Mr. Ruiz and Mr. McMurry.

13 Chairperson Talbott thanked Mr. Michalowski, Mr.
14 Ruiz, and Mr. McMurry for their work and offered them
15 Dr. Roussel's assistance.]

16 ***

17 Miscellaneous

18 [Terry M. Talbott, R.Ph., Chairperson, thanked Ms.
19 Zimmerman and staff for keeping Board operations going
20 during the COVID-19 pandemic.

21 Chairperson Talbott requested informing
22 inspectors that pharmacy inspections are informational
23 and not necessarily punitive, where a warning notice
24 may suffice.

25 Chairperson Talbott noted receiving a question in

1 chat concerning the CPR part of one of Governor Wolf's
2 waivers.

3 Mr. Ruiz will look into extending the current
4 December CPR expiration date to April.]

5 ***

6 Public Comment

7 [Chairperson Talbott announced Pat Epple's retirement
8 at the end of the year. She noted being deeply
9 grateful for Pat's leadership at PPA and welcomed
10 Vicky Elliott as the new PPA CEO.

11

12

13 There were additional comments regarding the
14 previous discussion concerning inspectors. It was
15 noted that many people engaged in compounding were
16 subject to the FDA sanitary conditions with a whole
17 section on chemical contamination. It was noted that
18 the inspectors determine whether the FDA sanitary
19 conditions were fair game for anybody to question in
20 any compounding environment.]

21 ***

22 Adjournment

23 CHAIRPERSON TALBOTT:

24 I will entertain a motion to adjourn.

25 MS. HART:

1 Motion to adjourn.

2 CHAIRPERSON TALBOTT:

3 Second?

4 MR. FRANKIL:

5 Second.

6 CHAIRPERSON TALBOTT:

7 All in favor, signify by saying aye.

8 [The motion carried unanimously.]

9 ***

10 [There being no further business, the State Board of
11 Pharmacy Meeting adjourned at 12:01 p.m.]

12 ***

13

14

15

16

17

18

19

20

21

22

23

24

25

26

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

CERTIFICATE

I hereby certify that the foregoing summary minutes of the State Board of Pharmacy meeting, was reduced to writing by me or under my supervision, and that the minutes accurately summarize the substance of the State Board of Pharmacy meeting.



Derek Richmond,
Minute Clerk
Sargent's Court Reporting
Service, Inc.

STATE BOARD OF PHARMACY
REFERENCE INDEX

December 1, 2020

	TIME	AGENDA
1		
2		
3		
4		
5		
6		
7		
8		
9	9:00	Executive Session
10		
11	10:30	Return to Open Session
12		
13	10:33	Official Call to Order
14		
15	10:33	Introduction of Board Members/Audience
16		
17	10:42	Report of Prosecutorial Division
18		
19	10:55	Appointment - Kimberly Adams, Chief of
20		Fiscal Management, Bureau of Finance
21		and Operations Annual Budget
22		Presentation
23		
24	11:05	Approval of Minutes
25		
26	11:06	Report of Board Counsel
27		
28	11:16	Report of Chairperson
29		
30	11:26	Report of Commissioner
31		
32	11:29	Report of Executive Secretary
33		
34	11:34	Applications
35		
36	11:37	New Business
37		
38	11:39	For the Board's Information
39		
40	11:40	Report of Board Counsel (Continued)
41		
42	11:52	Miscellaneous
43		
44	11:55	Public Comment
45		
46	12:01	Adjournment
47		
48		
49		
50		